Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Coherus Oncology (CHRS) over the last 10 years, with Q3 2025 value amounting to $37.0 million.

  • Coherus Oncology's Non-Current Debt rose 92.58% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 92.58%. This contributed to the annual value of $36.7 million for FY2024, which is 8511.12% down from last year.
  • Coherus Oncology's Non-Current Debt amounted to $37.0 million in Q3 2025, which was up 92.58% from $36.9 million recorded in Q2 2025.
  • Coherus Oncology's Non-Current Debt's 5-year high stood at $246.5 million during Q4 2023, with a 5-year trough of $36.5 million in Q2 2024.
  • Its 5-year average for Non-Current Debt is $128.0 million, with a median of $74.7 million in 2021.
  • In the last 5 years, Coherus Oncology's Non-Current Debt soared by 32339.27% in 2022 and then crashed by 8514.37% in 2024.
  • Over the past 5 years, Coherus Oncology's Non-Current Debt (Quarter) stood at $75.5 million in 2021, then surged by 225.09% to $245.5 million in 2022, then grew by 0.41% to $246.5 million in 2023, then tumbled by 85.11% to $36.7 million in 2024, then grew by 0.71% to $37.0 million in 2025.
  • Its Non-Current Debt was $37.0 million in Q3 2025, compared to $36.9 million in Q2 2025 and $36.8 million in Q1 2025.